Realtime | Geld | Brief | Zeit |
---|---|---|---|
0,245 | 0,296 | 22.07. |
Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Do | Cantargia Announces Preliminary Topline Efficacy Results From the Phase 2 TRIFOUR Trial of Nadunolimab in Advanced Triple-Negative Breast Cancer | 277 | ACCESS Newswire | LUND, SWEDEN / ACCESS Newswire / July 17, 2025 / Cantargia (STO:CANTA)Nadunolimab added to carboplatin and gemcitabine (GC) did not impact the safety profile of the chemotherapy and was well tolerated... ► Artikel lesen | |
CANTARGIA Aktie jetzt für 0€ handeln | |||||
16.07. | Cantargia Announces Publication of Clinical Data Showing Benefit of Nadunolimab Combination Therapy in Advanced Lung Cancer | 223 | ACCESS Newswire | LUND, SE / ACCESS Newswire / July 16, 2025 / Cantargia (STO:CANTA)Promising efficacy data with median PFS of 7.2 months (95%CI 5.6-9.2), median OS of 13.7 months (95%CI 11.1-18.3), and 1-year survival... ► Artikel lesen | |
15.07. | Otsuka to acquire Cantargia's CAN10 for autoimmune diseases | 3 | Pharmaceutical Technology | ||
15.07. | Cantargia Announces the Acquisition of its CAN10 IL1RAP Immunology Program by Otsuka Pharmaceutical | 289 | ACCESS Newswire | Cantargia receives an upfront cash payment of USD 33 million.Cantargia is eligible to receive up to USD 580 million in development, regulatory and commercial milestone payments plus earn-out payments... ► Artikel lesen | |
17.06. | Cantargia Signs SEK 50 Million Financing Facility Agreement, Extending Cash Runway Into 2026 and Providing Operating Flexibility to Drive Strategic Plans | 289 | ACCESS Newswire | LUND, SE / ACCESS Newswire / June 17, 2025 / Cantargia (STO:CANTA) - Cantargia (Cantargia AB (publ); Nasdaq Stockholm: CANTA) today announced that it has entered into a loan agreement of SEK 50 million... ► Artikel lesen | |
17.06. | Cantargia Q1 2025 slides: CAN10 advances amid funding challenges | 3 | Investing.com | ||
11.06. | Cantargia's Nadunolimab Aantibody Awarded US FDA Fast Track Designation | 717 | ACCESS Newswire | Fast Track Designation (FTD) granted for the treatment of patients with metastatic PDAC with high IL1RAP expression levels.Reflects high unmet medical need in metastatic PDAC.Facilitates further development... ► Artikel lesen | |
19.05. | Cantargia Publishes Promising Preclinical Results Highlighting CAN10's Potential to Inhibit Vascular Inflammation | 224 | ACCESS Newswire | IL1RAP expression positively correlates with inflammatory markers in human atherosclerotic plaques.IL1RAP blocking antibodies inhibit endothelial activation and neutrophil adhesion induced by IL-1,... ► Artikel lesen | |
15.05. | Bulletin from the Annual General Meeting in Cantargia AB | 287 | ACCESS Newswire | LUND, SWEDEN / ACCESS Newswire / May 15, 2025 / The Annual General Meeting of Cantargia (STO:CANTA) on May 15, 2025 resolved in accordance with the following:That no dividend would be paid.To discharge... ► Artikel lesen | |
13.05. | Cantargia Publishes Interim Report for the First Quarter of 2025 | 427 | ACCESS Newswire | LUND, SE / ACCESS Newswire / May 13, 2025 / Cantargia (STO:CANTA) - Cantargia (Cantargia AB (publ); Nasdaq Stockholm: CANTA) today announced its interim report for the first quarter of 2025."The first... ► Artikel lesen | |
12.05. | Cantargia Announces Successful Phase 1 Results: PK/PD Data of Subcutaneously Administered CAN10 Confirms Every 4-Week Dosing Choice in Phase 2 | 235 | ACCESS Newswire | LUND, SE / ACCESS Newswire / May 12, 2025 / Cantargia (STO:CANTA)Pharmacokinetic (PK) model generated based on the single ascending dose (SAD) data and the first multiple ascending dose (MAD) cohort.Model... ► Artikel lesen | |
06.05. | Cantargia's Announces Publication of Clinical Data Demonstrating Potential of Nadunolimab Plus Pembrolizumab in Solid Tumors | 269 | ACCESS Newswire | LUND, SE / ACCESS Newswire / May 6, 2025 / Cantargia (STO:CANTA)Results published in the peer-reviewed journal Investigational New DrugsStudy in heavily pre-treated patients with solid tumor indications... ► Artikel lesen | |
29.04. | Invitation to the Presentation of Cantargia's Interim Report for Q1 2025 | 231 | ACCESS Newswire | LUND, SE / ACCESS Newswire / April 29, 2025 / Cantargia (STO:CANTA) - Cantargia (Cantargia AB (publ); Nasdaq Stockholm:CANTA) will publish the company's interim report for the first quarter of 2025... ► Artikel lesen | |
29.04. | Cantargia Announces Selection of Treatment Resistant Atopic Dermatitis as Second Target Indication for CAN10 | 219 | ACCESS Newswire | LUND, SE / ACCESS Newswire / April 29, 2025 / Cantargia (STO:CANTA)Atopic dermatitis (AD) is a very common, heterogeneous and debilitating disease with a need for new treatment optionsCAN10 targets... ► Artikel lesen | |
28.04. | Cantargia Announces the Publication of Preclinical Data Highlighting Nadunolimab's Potential to Counteract Tumor-Driven Systemic Immunosuppression | 119 | ACCESS Newswire | LUND, SE / ACCESS Newswire / April 28, 2025 / Cantargia (STO:CANTA)Preclinical data shows IL1 family signals mediate systemic immune suppression.Blocking IL1RAP can overcome resistance to immune therapy... ► Artikel lesen | |
25.04. | Cantargia Presents Promising Preclinical Results on Anti-IL1RAP Antibody-Drug Conjugate at a Major Cancer Conference | 430 | ACCESS Newswire | Anti-IL1RAP ADC demonstrated potent anti-tumor efficacy and was well tolerated in pre-clinical modelsAnti-IL1RAP ADC targets IL1RAP, which is overexpressed in many tumors and their tumor microenvironment... ► Artikel lesen | |
25.04. | Cantargia Presents Association Between Nadunolimab and Reduction of Chemotherapy Induced Peripheral Neuropathy at AACR | 370 | ACCESS Newswire | LUND, SE / ACCESS Newswire / April 25, 2025 / Cantargia (STO:CANTA)Clinical findings show association between nadunolimab and lower incidence and later onset of CIPNPreclinical data show prevention... ► Artikel lesen | |
11.04. | Cantargia Publishes Annual Report 2024 | 326 | ACCESS Newswire | LUND, SE / ACCESS Newswire / April 11, 2025 / Cantargia (STO:CANTA) - Cantargia (Cantargia AB (publ); Nasdaq Stockholm:CANTA) today announced that the annual report for 2024 has been published. The... ► Artikel lesen | |
11.04. | Notice of Annual General Meeting in Cantargia AB | 284 | ACCESS Newswire | LUND, SE / ACCESS Newswire / April 11, 2025 / Cantargia (STO:CANTA) - The shareholders of Cantargia AB (publ) are invited to the annual general meeting on Thursday, 15 May 2025, at 15.00 CEST at Ideon... ► Artikel lesen | |
01.04. | Cantargia appoints Morten Lind Jensen as Chief Medical Officer | 249 | ACCESS Newswire | LUNDE, SE / ACCESS Newswire / April 1, 2025 / Cantargia (STO:CANTA) - Cantargia AB (publ) ("Cantargia") (Nasdaq Stockholm:CANTA) today announced the appointment of Morten Lind Jensen, MD, PhD, as Chief... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 94,90 | +0,21 % | BioNTech: Ryan Richardson verlässt Vorstand im Herbst | Bei BioNTech steht ein Wechsel im Vorstand bevor. Ryan Richardson wird seine Position als Chief Strategy Officer sowie seine Ämter in Tochtergesellschaften der BioNTech-Gruppe zum 30. September 2025... ► Artikel lesen | |
EVOTEC | 6,230 | +0,48 % | Evotec-Aktie mit Kursgewinnen (7,326 €) | Am deutschen Aktienmarkt liegt die Aktie von Evotec aktuell im Plus. Der jüngste Kurs betrug 7,33 Euro. Für das Wertpapier von Evotec steht gegenwärtig ein Wertanstieg 0,33 Prozent zu Buche. Die Aktie... ► Artikel lesen | |
QIAGEN | 41,560 | +1,24 % | QIAGEN N.V.: QIAGEN Expands NGS Portfolio with Launch of QIAseq xHYB Long Read Panels | Expansion of QIAseq portfolio to Long Read Panels enables high-resolution analysis of complex genomic regions using long-read sequencing Supports NGS platforms such as PacBio for applications... ► Artikel lesen | |
REGENERON PHARMACEUTICALS | 473,80 | -0,71 % | Regeneron Stock Plunges 22.6% YTD: Should You Buy, Sell or Hold? | ||
BRAIN BIOTECH | 2,460 | +0,82 % | Brain Biotech +30%: Das ist der Grund! | Die Aktie der Brain Biotech AG explodiert heute wie aus dem Nichts. Wir kennen die Hintergründe zum Kursspektakel und haben gleich bessere Tipps parat. Aktuell rund 30% bis auf über 2,50 € geht es für... ► Artikel lesen | |
SCORPIUS | 0,072 | 0,00 % | Scorpius Holdings, Inc.: Scorpius Holdings Announces Corporate Update Including Cost Optimization Initiatives, Strategic Corporate Developments, and Potential Opportunities for Expansion into Southeast Asia | Operational Realignment Expected to Deliver Over $6 Million in Annual Cost Savings Company Exploring CDMO Expansion Opportunities in Southeast Asia San Antonio, TX, May 04, 2025 (GLOBE NEWSWIRE)... ► Artikel lesen | |
CARDIOL THERAPEUTICS | 1,196 | +0,34 % | Cardiol Therapeutics Inc.: Cardiol Therapeutics Announces Database Lock for Phase II ARCHER Trial of CardiolRx in Acute Myocarditis | ARCHER is designed to assess the impact of CardiolRx on cardiac magnetic resonance imaging parameters that measure heart dysfunction and edema/fibrosis-key measurements used to predict prognosis in... ► Artikel lesen | |
BURCON NUTRASCIENCE | 1,690 | -4,74 % | Burcon NutraScience Corporation: Burcon to Showcase Chipotle Black Bean Protein Hummus at 2025 IFT FIRST Annual Event & Expo | Vancouver, British Columbia--(Newsfile Corp. - July 10, 2025) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) ("Burcon" or the "Company"), a global technology leader in plant-based protein... ► Artikel lesen | |
CSL | 144,98 | -0,59 % | Should I still swap my CSL for CBA shares or has the market corrected? | ||
MANNKIND | 3,266 | -2,45 % | H.C. Wainwright assumes coverage on MannKind stock with Buy rating | ||
OCULAR THERAPEUTIX | 9,878 | +0,55 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Unveils New Corporate Branding, Reflecting its Transformation to a Retina-Focused Company |
BEDFORD, Mass., June 26, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, "Ocular"), a biopharmaceutical company committed to redefining the retina experience, announced the launch... ► Artikel lesen | |
OXFORD NANOPORE TECHNOLOGIES | 2,120 | +0,24 % | FTSE 250 movers: Oxford Nanopore surges; Mony Group slides | ||
ADAPTIMMUNE THERAPEUTICS | 0,230 | -0,86 % | Adaptimmune Therapeutics PLC - 8-K, Current Report | ||
CODEXIS | 2,650 | +2,24 % | Codexis, Inc.: Codexis Announces New Employment Inducement Grants | REDWOOD CITY, Calif., March 07, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced... ► Artikel lesen | |
TELO GENOMICS | 0,052 | -5,45 % | Telo Genomics Corp. to File Statement of Defence and Counterclaim to Lawsuit Filed by Former President | Toronto, Ontario--(Newsfile Corp. - June 30, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics") has received a Statement of Claim filed by Sherif Louis, the... ► Artikel lesen |